Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telisotuzumab vedotin - AbbVie

Next Previous
Drug Profile

Telisotuzumab vedotin - AbbVie

Alternative Names: ABBV-399; ABT 399; EMRELIS; Teliso-V; Telisotuzumab vedotin-tllv; Telisotuzumab-vedotin

Latest Information Update: 19 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer
  • No development reported Solid tumours
  • Discontinued Squamous cell cancer

Most Recent Events

  • 07 Jan 2026 Jonsson Comprehensive Cancer Center in collaboration with AbbVie plans phase II trial in Non small cell lung cancer (Second-line therapy and greater) (IV) (NCT07323641)
  • 17 Oct 2025 Updated efficacy and adverse events data from the phase II LUMINOSITY trial in Non-small cell lung cancer presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
  • 14 Sep 2025 Drug interaction data from a phase I/Ib trial in Solid tumours presented at the American College of Clinical Pharmacology Annual Meeting (ACCP-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top